Seven Fleet Capital Management LP Invests $783,000 in Celcuity, Inc. $CELC

Seven Fleet Capital Management LP bought a new stake in Celcuity, Inc. (NASDAQ:CELC) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 7,849 shares of the company’s stock, valued at approximately $783,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CELC. EverSource Wealth Advisors LLC boosted its holdings in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares in the last quarter. US Bancorp DE raised its stake in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after buying an additional 143 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after buying an additional 1,167 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Celcuity in the 4th quarter valued at approximately $42,000. Finally, Ogorek Anthony Joseph NY ADV boosted its stake in shares of Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after buying an additional 109 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Performance

CELC opened at $87.76 on Friday. Celcuity, Inc. has a 1-year low of $11.27 and a 1-year high of $151.02. The stock has a market cap of $4.28 billion, a P/E ratio of -22.50 and a beta of 0.10. The stock’s 50 day simple moving average is $117.74 and its 200 day simple moving average is $110.95. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities analysts anticipate that Celcuity, Inc. will post -3.69 EPS for the current fiscal year.

Analysts Set New Price Targets

CELC has been the topic of a number of recent analyst reports. Leerink Partners set a $155.00 price objective on Celcuity in a report on Tuesday, June 2nd. Wolfe Research restated an “outperform” rating and set a $110.00 target price on shares of Celcuity in a research report on Thursday, March 12th. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Stifel Nicolaus set a $150.00 price target on shares of Celcuity in a report on Monday, May 4th. Finally, Craig Hallum reduced their price objective on shares of Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $152.09.

Insider Buying and Selling at Celcuity

In other news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares in the company, valued at $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,000 shares of company stock worth $5,111,950 in the last three months. 13.33% of the stock is owned by corporate insiders.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.